惯性聚合 高效追踪和阅读你感兴趣的博客、新闻、科技资讯
阅读原文 在惯性聚合中打开

推荐订阅源

爱范儿
爱范儿
量子位
大猫的无限游戏
大猫的无限游戏
小众软件
小众软件
J
Java Code Geeks
B
Blog
V
V2EX
博客园 - 三生石上(FineUI控件)
Blog — PlanetScale
Blog — PlanetScale
aimingoo的专栏
aimingoo的专栏
Y
Y Combinator Blog
F
Fortinet All Blogs
OSCHINA 社区最新新闻
OSCHINA 社区最新新闻
The Cloudflare Blog
A
About on SuperTechFans
D
DataBreaches.Net
阮一峰的网络日志
阮一峰的网络日志
博客园 - Franky
H
Help Net Security
宝玉的分享
宝玉的分享
Martin Fowler
Martin Fowler
酷 壳 – CoolShell
酷 壳 – CoolShell
MongoDB | Blog
MongoDB | Blog
L
LangChain Blog

All Articles on Seeking Alpha

All Eyes On Cencora, A Healthcare Supplier That Could See Lots More Upside Simply Good Foods Doesn't Look Like A Growth Stock Anymore Applied Digital: Post-Earnings Clarity Confirms An Accelerated Path To $1 Billion NOI Target IBIT: Why I Stepped To The Side (Technical Analysis) (Rating Downgrade) XES: Oil Service Stocks Turn Pricey; Why It's Time To Take Profits (Rating Downgrade) The Only Dividend Strategy I'd Trust In A 3.5% Fed Funds World Opera: AI-Driven Advertising Prospects - Upside Potential And Rich Dividend Yields RenaissanceRe: Preferred Stock Hasn't Been This Appealing In Years Q1 Earnings Kick Off With Major Banks' Results: Bank of America, Netflix In Focus Sezzle: Consolidation Completed, Re-Rating Ahead Bitmine Immersion Q2 Preview: Ethereum Thesis Facing Important Report Card I Am Sharing 2 Of My Retirement High-Yield Gems The Software Narrative Is Leaking Badly Again Thanks To Anthropic Mythos The Muni Market Looks Appealing In Q2 AVIV: Should Keep Rising If The Ceasefire Holds Foundayo Explained: Lilly's New Weight Loss Pill And The Amazon Effect Sabesp: A New Privatization As An Opportunity! EchoStar: Potential Bull Trap At Play - Take Gains Off The Table Teladoc Health: Improving Fundamentals Support A Turnaround Story March CPI Inflation: 5 Reasons To Stay Calm Two 12%+ Yielding BDC Bargains (One Is My Top Deep-Value Pick) TechnipFMC: We Prefer Saipem With More Room To Improve Tesla: From Bye-Bye To Buy-Buy (Rating Upgrade) DMB: Vulnerable To High Interest Rates Western Midstream: A 9% Yield That Still Grows In A Downturn IQQQ: Tax-Efficient Income From The Nasdaq But Does Not Protect Against Declines Qualys Share Price Pulled Down By Potential Cybersecurity Disruptor S&P 500: A Dead Money Era May Be Here. How To Thrive In It Vistance Networks Looks Better Than Before With Powerful Earnings Growth Commerce Bancshares: Valuation, Not Quality, Is The Problem
Smith & Nephew plc (SNN) Shareholder/Analyst Call Transcript
SA Transcripts · 2026-06-11 · via All Articles on Seeking Alpha

Smith & Nephew plc (SNN) Shareholder/Analyst Call June 9, 2026 3:30 AM EDT

Company Participants

Emily Heaven - Head of Investor Relations
Deepak Nath - CEO & Director
Cathy Dalene
Christie Van Geffen
Mayank Shandil
Scott Gunn
John Rogers - CFO & Executive Director
Scott Schaffner - President of Sports Medicine

Conference Call Participants

Ravi Bashyal
Kane Slutzkin - Deutsche Bank AG, Research Division
David Adlington - JPMorgan Chase & Co, Research Division
Dr. Anil Ranawat
Graham Doyle - UBS Investment Bank, Research Division
Steve Haas
Veronika Dubajova
Michael Ast - Hospital for Special Surgery
Dr. Christopher Scott Klifto
Sebastien Jantet - Panmure Liberum Limited, Research Division
Charles Weston - RBC Capital Markets, Research Division
Veronika Dubajova - Citigroup Inc., Research Division
Julien Ouaddour - BofA Securities, Research Division

Conversation

Emily Heaven
Head of Investor Relations

Good morning, everyone, and welcome to those joining on the webcast. I'm Emily Heaven, Head of Investor Relations, and it's a pleasure to have you with us for our Expert Surgeon Insights Event. We have a strong lineup this morning, including presentations from 5 renowned surgeons. During the breaks, I'd encourage you to visit our product fair next door, and there'll be a light lunch for those able to stay after.

And now let me hand over to our CEO, Deepak Nath.

Deepak Nath
CEO & Director

Thank you, Emily. Let me add my warm welcome to you all. So it's great to have you with us here in London as we mark our 170th year as a company to showcase our innovation that's driving better patient outcomes and ultimately supporting our growth. So you'll hear from leaders across our business, demonstrating the strength of our portfolio and importantly, from surgeons themselves, the people using our products every day about what truly differentiates our offerings in practice.

As many of you know, our RISE strategy to accelerate growth and improve returns is focused